Tear protein biomarkers of refractive surgery pain

屈光手术疼痛的泪液蛋白生物标志物

基本信息

批准号：
10786192
负责人：
SUE A AICHER
金额：
$ 88.37万
依托单位：
OREGON HEALTH & SCIENCE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-01 至 2026-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10786192
关键词：
Ablation Acute Pain Age Algorithms American Bathing Biological Biological Assay Biological Markers Biometry Categories Clinical Collection Consensus Cornea Corneal Injury Corneal pain Detection Development Diagnostic Disease Disease Progression Excision Eye Eye diseases Feeling suicidal Future Goals Hour In Situ Individual Knowledge Lasers Link Lipids Liquid substance Mass Spectrum Analysis Measures Mental Health Methods Morbidity - disease rate Nerve Nociception Non-Steroidal Anti-Inflammatory Agents Normal Range Numeric Rating Scale Operative Surgical Procedures Ophthalmologic Surgical Procedures Opioid Oral Outcome Pain Pain Measurement Pain management Participant Patients Persistent pain Phase Photorefractive Keratectomy Population Postoperative Pain Probability Procedures Prognostic Marker Protein Analysis Proteins Proteomics Quality of life Refractive Errors Reporting Reproducibility Risk Sampling Sensory Nerve Endings Smoking Status Source Suicide Surface Therapeutic Treatment Efficacy United States Validation Variant Vision Visit Vulnerable Populations Water Work analytical method antinociception biomarker signature biomarker validation combat corneal ablation corneal epithelium diagnostic biomarker experience eye dryness improved keratomileusis ocular pain pain reduction pain score patient population patient screening patient stratification predictive marker prognostic prognostication protein biomarkers recruit resilience response sex surgical pain tear proteins

项目摘要

PROJECT SUMMARY Photorefractive keratectomy (PRK) and laser-assisted in situ keratomileusis (LASIK) are surgical procedures used to correct refractive errors, with approximately 600,000 surgeries performed in the United States each year. A proportion (10 - 20%) of individuals develop persistent ocular pain after refractive surgery, which is a source of tremendous morbidity, limiting the ability to work, impacting mental health, and leading to suicidal ideation in severe cases. We hypothesize that proteins in the tear fluid modulate corneal nerve function, increasing the risk of and contributing to persistent pain after refractive surgery. As such, our studies will use proteomic analysis of tear fluid after surgery to identify diagnostic biomarkers for persistent ocular pain. We will also examine tear proteins prior to surgery in an effort to identify prognostic biomarkers that predict which individuals are likely to develop persistent pain after surgery. R33 Phase studies will use an alternative proteomics platform for analytical validation, and an additional new patient population for clinical validation. This knowledge can lead to better preventative and therapeutic algorithms to combat this debilitating condition and thus improve quality of life and decrease patient suffering.

项目摘要光疗法角膜切除术（PRK）和激光辅助原位角膜肌（Lasik）是用于纠正折射错误的手术程序，大约有60万手术每年在美国表演。一定比例（10-20％）发展折射手术后的持续性眼痛，这是巨大发病率的来源限制工作能力，影响心理健康，并导致严重的自杀念头案例。我们假设泪液调节角膜神经功能中的蛋白质，增加屈光手术后持续疼痛的风险和促进。因此，我们的研究将在手术后使用泪液的蛋白质组学分析来鉴定诊断生物标志物持续的眼部疼痛。我们还将在手术前检查撕裂蛋白，以识别预后的生物标志物可以预测哪些人可能会在外科手术。 R33相研究将使用替代蛋白质组学平台进行分析验证，以及额外的新患者人群进行临床验证。这些知识可以导致更好的预防和治疗算法，以应对这种令人衰弱的状况，从而解决改善生活质量并减少患者的痛苦。